Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Eterna Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Sanjeev Luther

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.4yrs

Son yönetim güncellemeleri

Recent updates

Brooklyn Immunotherapeutics announces name change to Eterna Therapeutics

Oct 11

Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results

Jul 26

CEO

Sanjeev Luther (62 yo)

less than a year

Görev süresi

Mr. Sanjeev Luther served as the Chief Executive Officer, President & Director at Cornerstone Pharmaceuticals, Inc. (formerly known as Rafael Pharmaceuticals, Inc.). until 2024 and also served as Chairman...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sandra Gurrola	Principal Financial & Accounting Officer and Senior VP of Finance	2.4yrs	US$305.88k	0.022% $ 1.2k
Sanjeev Luther	CEO, President & Director	less than a year	Veri yok	Veri yok
Robert Pierce	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Dorothy Clarke	General Counsel & Director	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: ERNA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sanjeev Luther	CEO, President & Director	less than a year	Veri yok	Veri yok
Dorothy Clarke	General Counsel & Director	1.2yrs	Veri yok	Veri yok
Sol Barer	Advisor to the Board	no data	Veri yok	Veri yok
William Wexler	Independent Director	2.3yrs	US$112.29k	0% $ 0
Michael Andreeff	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
James Bristol	Independent Chairman of the Board	less than a year	Veri yok	Veri yok
Jeffrey Karp	Member of Scientific Advisory Board	1.6yrs	Veri yok	Veri yok
Christopher Rohde	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
Peter Cicala	Independent Director	less than a year	Veri yok	Veri yok

1.4yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ERNA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Eterna Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Eterna Therapeutics Inc., Annual General Meeting, Sep 27, 2024

Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board

Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors

Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee

Eterna Therapeutics Inc. Announces Management Changes

Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board

Recent updates

New minor risk - Share price stability

Eterna Therapeutics Inc. announced that it has received $3.9 million in funding

Eterna Therapeutics Provides Non-Compliance Update

Eterna Therapeutics Inc., Annual General Meeting, Sep 27, 2024

Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board

Eterna Therapeutics Inc. to Present at the ASGCT 27Th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line

Eterna Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Financial position

Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors

Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee

Eterna Therapeutics Inc. Announces Management Changes

Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board

New major risk - Share price stability

Eterna Therapeutics Inc. Appoints James Bristol to Its Board of Directors

New major risk - Market cap size

Eterna Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5605, Requires the Audit Committee to Consist of at Least Three Members

Eterna Therapeutics Inc. Appoints Ms. Dorothy J. Clarke as Director, Effective on August 28, 2023

Eterna Therapeutics Inc. Announces Management Changes

Eterna Therapeutics Inc. Announces Board Changes

Eterna Therapeutics Inc. Appoints Megan Yung as Chief Strategy Officer, General Counsel

Eterna Therapeutics Inc., Annual General Meeting, Jun 16, 2023

Eterna Therapeutics Inc. Appoints Dimitrios Goundis, Ph.D to the Committee on Board Focusing on Business Development

Eterna Therapeutics Inc. Announces the Resignation of Roger Sidhu as Chief Medical Officer, Effective on January 31, 2023

Eterna Therapeutics Inc. Appoints Matt Angel as President

Insider recently bought US$1.1m worth of stock

Eterna Therapeutics Receives A Non-Compliance Notice from Nasdaq Regarding Stockholders' Equity Requirement

High number of new and inexperienced directors

Brooklyn Immunotherapeutics announces name change to Eterna Therapeutics

Brooklyn Immunotherapeutics, Inc. Announces Resignation of Kevin D’Amour as Chief Scientific Officer

Price target decreased to US$3.00

High number of new and inexperienced directors

Brooklyn ImmunoTherapeutics, Inc. Announces the resignation of Kevin D’Amour as Chief Scientific Officer

Brooklyn ImmunoTherapeutics, Inc. Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results

Brooklyn ImmunoTherapeutics Receives Non-Compliance Letter from Nasdaq

Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Value Index

Brooklyn ImmunoTherapeutics, Receives Non-Compliance Letter from Nasdaq

Brooklyn ImmunoTherapeutics, Inc. Announces Executive Changes

Brooklyn ImmunoTherapeutics, Inc. Announces Board Changes

Brooklyn Immunotherapeutics Announces Executive Changes

Brooklyn Immunotherapeutics Announces Executive Management Changes

Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q

Brooklyn ImmunoTherapeutics, Inc. announced delayed 10-Q filing

Brooklyn ImmunoTherapeutics, Inc. to Report Q4, 2021 Results on Apr 15, 2022

Brooklyn ImmunoTherapeutics, Inc. announced delayed annual 10-K filing

Chairman recently sold US$6.3m worth of stock

Chairman notifies of intention to sell stock

Director notifies of intention to sell stock

Brooklyn Immuno Therapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research

Brooklyn Immunotherapeutics Acquires License for Mrna Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş